The suicide prevention effect of lithium: More than 20 years of evidence—a narrative review

International Journal of Bipolar Disorders

Volumn 3, Issue 1, 2015, Pages

  Lewitzka, U ^a   Severus, E ^a   Bauer, R ^a   Ritter, P ^a   Muller Oerlinghausen B ^b   Bauer, M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Drug Commission of the German Medical Association   (Germany)

Author keywords

Affective disorders; Bipolar disorders; Depression; Lithium; Mortality; Prevention; Suicide; Suicide attempt

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; PHENELZINE;

ARTICLE; BIPOLAR DISORDER; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DEATH; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TREATMENT RESPONSE;

EID: 85047601485     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/s40345-015-0032-2     Document Type: Article

References (82)

1. AFSP. Facts and figures. 2014 [http://www.afsp.org/understanding-suicide/facts-and-figures]. Accessed 07 June 2015.
2. Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry. 2001;34:132–6.
3. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years’ follow-up. Arch Suicide Res. 2005;9:279–300.
4. Arsenault-Lapierre G, Kim C, Turecki G. Psychiatric diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry. 2004;4:37.
5. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry. 1999;60 Suppl 2:77–84. discussion 111–6.
6. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006;8:625–39.
7. Barraclough B. Suicide prevention, recurrent affective disorder and lithium. Br J Psychiatry. 1972;121:391–2.
8. Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle A, Müller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry. 2000;157:1429–35.
9. Blüml V, Regier MD, Hlavin G, Rockett IR, König F, Vyssoki B, et al. Lithium in the public water supply and suicide mortality in Texas. J Psychiatr Res. 2013;47:407–11.
10. Bocchetta A. Mortality follow-up of patients since commencing lithium therapy. J Clin Psychopharmacol. 2005;25:197–9.
11. Bocchetta A, Ardau R, Burrai C, Chillotti C, Quesada G, Del Zompo M. Suicidal behaviour on and off lithium prophylaxis in a group of patients with prior suicide attempts. J Clin Psychopharmacol. 1998;18:384–9.
12. Brodersen A, Licht RW, Vestergaard P, Olesen AV, Mortensen PB. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry. 2000;176:429–33.
13. Bschor T, Lewitzka U, Pfennig, Bauer M. Twenty-five years of lithium augmentation. Nervenarzt. 2007;78:1237–47.
14. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013–24.
15. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. Psychol Med. 2003;33:395–405.
16. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry. 2005;162:1805–19.
17. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.
18. Collins JC, McFarland BH. Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. J Affect Disord. 2008;107:23–8.
19. Comai S, Tau M, Pavlovic Z, Gobbi G. The pharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol. 2012;32:237–60.
20. Conell J, Just R, Felber W. Suizidale Handlungen in einer Kohorte 20-jähriger Lithiumbehandlungen. 3. Mitteldeutsche Psychiatrietage „Stand der Ursachen-und Therapieforschung bei psychischen Erkrankungen“, Abstract Bd., Magedeburg, 16.-17. März 2001, S.17
21. Coppen A. Lithium in unipolar depression and the prevention of suicide. J Clin Psychiatry. 2000;9:52–6.
22. Coppen A, Noguera R, Bailey J, Burns BH, Swani MS, Hare EH, et al. Prophylactic lithium in affective disorders. Controlled Trial Lancet. 1971;2:275–9.
23. Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C. Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord. 1991;23:1–7.
24. Coryell W, Arndt S, Turvey C, Endicott J, Solomon D, Mueller T, et al. Lithium and suicidal behaviour in major affective disorder: a case–control study. Acta Psychiatr Scand. 2001;104:193–7.
25. De Leo D, Burgis S, Bertolote JM, Kerkhof AJ, Bille-Brahe U. Definitions of suicidal behavior. Lessons learned from the WHO/EURO multicentre study. Crisis. 2006;27:4–15.
26. Dorus W, Ostrow DG, Anton R, Cushman P, Collins JF, Schaefer M, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA. 1989;262:1646–52.
27. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013;38:743–52.
28. Felber W, Kyber A. Suizide und parasuizide während und außerhalb einer lithiumprophylaxe. In: Müller-Oerlinghausen B, Berghöfer A, editors. Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Georg Thieme Verlag: Stuttgart; 1994. p. 53–9.
29. Fieve RR. Clinical use of lithium in affective disorders. Drugs. 1977;13:458–66.
30. Findling RL, McNamara NK, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:409–17.
31. Fülle M, Felber W, Israel M. Untersuchung zur Medikation im Vorfeld psychiatrischer Kliniksuizide. 3. Mitteldeutsche Psychiatrietage „Stand der Ursachen-und Therapieforschung bei psychischen Erkrankungen“, Magedeburg 16.-17.März 2001, Abstract-Bd., S. 14
32. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. BALANCE investigators and collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375:385–95.
33. Giotakos O, Nisianakis P, Tsouvelas G, Giakalou VV. Lithium in the public water supply and suicide mortality in Greece. Biol Trace Elem Res. 2013;156:376–9.
34. Gonzales-Pinto A, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 2006;8:618–24.
35. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290:1467–73.
36. Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, et al. Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord. 1996;40:179–90.
37. Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel RR, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders—a randomised study. J Affect Disord. 1997a;43:151–61(a).
38. Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, et al. Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study. Eur Arch Psychiatry Clin Neurosci. 1997b;247:42–50(b).
39. Grof P, Alda M, Grof E, Fox D, Cameron P. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br J Psychiatry. 1993;21:16–9.
40. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14:154–219.
41. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68:380–3.
42. Hanus K, Zapletálek M. Suicidal activity of patients with affective disorders during the preventive use of lithium. Cesk Psychiatr. 1984;80:97–100.
43. Hawton K, Sutton L, Haw C, Sinclair J, Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry. 2005;66:693–704.
44. Kabacs N, Memon A, Obinwa T, Stochl J, Perez J. Lithium in drinking water and suicide rates across the East of England. Br J Psychiatry. 2011;198:406–7.
45. Kallner G, Lindelius R, Petterson U, Stockman O, Tham A. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry. 2000;33:8–13.
46. Kapusta ND, Mossaheb N, Etzersdorfer E, Hlavin G, Thau K, Willeit M, et al. Lithium in drinking water and suicide mortality. Br J Psychiatry. 2011;198:346–50.
47. Keks NA, Hill C, Sundram S, Graham A, Bellingham K, Dean B, et al. Evaluation of treatment in 35 cases of bipolar suicide. Aust N Z J Psychiatry. 2009;43:503–8.
48. Kessing LV, Søndergård L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry. 2005;62:860–6.
49. Khan A, Khan SR, Hobus J, Faucett J, Mehra V, Giller EL, et al. Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels. J Psychiatr Res. 2011;45:1489–96.
50. Kok RM, Vink D, Heeren TJ, Nolen WA. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open randomized controlled trial. J Clin Psychiatry. 2007;68:1177–85.
51. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III: pharmacopsychiatry. J Affect Disord. 2009;117:26–43.
52. Lauterbach E, Felber W, Müller-Oerlinghausen B, Ahrens B, Bronisch T, Meyer T, et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand. 2008;118:469–79.
53. Lee B, Kim YK. Potential peripheral biological predictors of suicidal behaviour in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;35:842–7.
54. Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord. 2010;12:483–93.
55. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;79:721–8.
56. Mühlbauer HD, Müller-Oerlinghausen B. Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: further evidence for a central serotonergic action of lithium in man. J Neural Transm. 1985;61:81–94.
57. Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology. 2010;62:43–9.
58. Müller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Lenz G, Schou M, et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand. 1992a;86:218–22(a).
59. Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord. 1992b;25:261–9(b).
60. Müller-Oerlinghausen B, Bauer M, Grof P. Commentary on a recent review of lithium toxicity: what are its implication for clinical practice? BMC Med. 2012;10:132.
61. Neuner T, Hübner-Liebermann B, Haen E, Hausner H, Felber W, Wittmann M, et al. Completed suicides in 47 hospitals in Germany—results from the AGATE-study. Pharmacopsychiatry. 2011;34:132–6.
62. Nilsson A. Mortality in recurrent mood disorders during periods on and off lithium. A complete population study in 362 patients. Pharmacopsychiatry. 1995;28:8–13.
63. Nordentoft M, Mortensen PB, Pedersen CB. Absolute risk for suicide after first hospital contact in mental disorder. Arch Gen Psychiatry. 2011;68:1058–64.
64. Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord. 2010;12:1–9.
65. Ohgami H, Terao T, Shiotsuki I, Ishii N, Iwata N. Lithium levels in drinking water and risk of suicide. Br J Psychiatry. 2009;194:464–5.
66. Ohmura Y, Tsutsui-Kimura I, Kumamoto H, Minami M, Izumi T, Yamaguchi T, et al. Lithium, but not valproic acid or carbamazepine, suppresses impulsive-like action in rats. Psychopharmacology (Berl). 2012;219:421–32.
67. Oquendo MA, Galfalvy HC, Currier D, Grunebaum MF, Sher L, Sullivan GM, et al. Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behaviour. Am J Psychiatry. 2011;168:1050–6.
68. Pfennig A, Bauer M. S3 guidelines on bipolar disorders are contemporary and important instruments for clinical practice. Nervenarzt. 2013;84:874–5.
69. Prien RF, Klett CJ, Caffey Jr EM. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry. 1973a;29:420–5(a).
70. Prien RF, Caffey Jr EM, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 1973b;28:337–41(b).
71. Schaffer A, Isometsä ET, Tondo L, H Moreno D, Turecki G, Reis C, et al. International Society for Bipolar Disorder Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord. 2015;17:1–16.
72. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. Immunological aspects in neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42:151–7.
73. Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG, et al. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impared blood–brain barrier integrity. World J Biol Psychiatry. 2012;13:482–92.
74. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162:1281–90.
75. Tondo L, Jamison KR, Baldessarini RJ. Effect of lithium maintenance on suicidal behaviour in major mood disorders. Ann N Y Acad Sci. 1997;836:339–51.
76. Vestergaard P, Aagaard J. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord. 1991;21:33–8.
77. Vita A, De Peri L, Sacchetti E. Lithium in drinking water and suicide prevention: a review of the evidence. Int Clin Psychotpharmacol. 2015;30:1–5.
78. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry. 2011;72:1452–64.
79. WHO. Preventing suicide: a resource for general physician. 2000 [http://www.who.int/mental_health/media/en/56.pdf?ua=1].
80. WHO. Preventing suicide: a global imperative. 2014 [http://www.who.int/mental_health/suicide-prevention/world_report_2014/en/].
81. Wilkinson D, Holmes C, Woolford J, Stammers S, North J. Prophylactic therapy with lithium in elderly patients with unipolar major depression. Int J Geriatr Psychiatry. 2002;17:619–22.
82. Wolf T, Müller-Oerlinghausen B, Ahrens B, Grof P, Schou M, Felber W, et al. How to interpret findings on mortality of long-term lithium treated manic-depressive patients?! Critique of different methodological approaches. J Affect Disord. 1996;39:127–32.